166 related articles for article (PubMed ID: 2614206)
1. [A case of thyrotropin-, growth hormone-, and prolactin-secreting pituitary adenoma with a remarkable response to long-acting somatostatin analogue (SMS201-995)].
Usui T; Sako Y; Matsumoto M; Kita T; Shimatsu A; Imura H
Nihon Naika Gakkai Zasshi; 1989 Nov; 78(11):1605-6. PubMed ID: 2614206
[No Abstract] [Full Text] [Related]
2. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
[TBL] [Abstract][Full Text] [Related]
3. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
[TBL] [Abstract][Full Text] [Related]
4. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Lee EJ; Kim KR; Lim SK; Lee HC; Kim DI; Kim SH; Huh KB
Eur J Endocrinol; 1994 Jul; 131(1):109-12. PubMed ID: 8038902
[TBL] [Abstract][Full Text] [Related]
5. Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.
Curtò L; Ragonese M; Losa M; Trimarchi F; Cannavò S
J Endocrinol Invest; 2010 Mar; 33(3):204-5. PubMed ID: 19609104
[No Abstract] [Full Text] [Related]
6. [Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma].
Murillo Sanchís J; Martín AL; Salinas Vert I; Sanmartí Sala A
Med Clin (Barc); 2000 Feb; 114(6):238. PubMed ID: 10757110
[No Abstract] [Full Text] [Related]
7. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
8. Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma.
Stiles MK; Conaglen JV; Speed J; Chatterton B
Aust N Z J Med; 1996 Feb; 26(1):122-3. PubMed ID: 8775545
[No Abstract] [Full Text] [Related]
9. Size changes of a growth hormone- and prolactin-producing adenoma during and after sandostatin treatment.
García-Luna PP; Leal del Cerro A; Santos C; Montero C; Acosta D; Navarro E; del Pozo E; Gómez-Pan A; Astorga R
Horm Res; 1988; 29(2-3):109-11. PubMed ID: 2900188
[TBL] [Abstract][Full Text] [Related]
10. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
11. Endocrine applications of the somatostatin analogue octreotide (Sandostatin).
Ezzat S; Melmed S
Metabolism; 1992 Sep; 41(9 Suppl 2):34-8. PubMed ID: 1518431
[No Abstract] [Full Text] [Related]
12. Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin.
Felix I; Asa SL; Kovacs K; Horvath E; Smyth HS
Arch Pathol Lab Med; 1994 Jan; 118(1):66-70. PubMed ID: 8285835
[TBL] [Abstract][Full Text] [Related]
13. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
Orme SM; Lamb JT; Nelson M; Belchetz PE
Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.
Colao A; Filippella M; Di Somma C; Manzi S; Rota F; Pivonello R; Gaccione M; De Rosa M; Lombardi G
Endocrine; 2003 Apr; 20(3):279-83. PubMed ID: 12721508
[TBL] [Abstract][Full Text] [Related]
15. An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
Meas T; Sobngwi E; Vexiau P; Boudou P
Ann Endocrinol (Paris); 2006 Jun; 67(3):249-52. PubMed ID: 16840917
[TBL] [Abstract][Full Text] [Related]
16. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
[TBL] [Abstract][Full Text] [Related]
17. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment.
Polak M; Bertherat J; Li JY; Kujas M; Le Dafniet M; Weizani H; Van Effenterre R; Epelbaum J; Turpin G
Acta Endocrinol (Copenh); 1991 Apr; 124(4):479-86. PubMed ID: 1851593
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas.
Anniko M; Werner S; Wersäll J
Acta Otolaryngol; 1981; 92(3-4):343-55. PubMed ID: 7324902
[No Abstract] [Full Text] [Related]
19. Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin- and prolactin-secreting pituitary adenoma.
Adriaanse R; Brabant G; Endert E; Bemelman FJ; Wiersinga WM
Eur J Endocrinol; 1994 Feb; 130(2):113-20. PubMed ID: 8130883
[TBL] [Abstract][Full Text] [Related]
20. Escape phenomenon after successful bromocriptine and octreotide treatment in thyroid stimulating hormone secreting pituitary adenoma residual tissue.
De Rosa G; Testa A; Giacomini D; Carrozza C
Eur J Cancer; 1994; 30A(2):247-8. PubMed ID: 8155399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
